Myeloproliferative Neoplasms

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

The European Commission has approved luspatercept-aamt (Reblozyl) as a treatment for patients with transfusion-dependent anemia from very low-, low-, and intermediate-risk myelodysplastic syndromes with ring sideroblasts who had unsatisfactory response or are not candidates for erythropoietin-based therapy, and patients with transfusion-dependent anemia linked with beta thalassemia.

The novel BET inhibitor CPI-0610 demonstrated clinical activity with or without ruxolitinib in patients with JAK inhibitor-naïve and JAK inhibitor-exposed or -intolerant myelofibrosis.

Jorge E. Cortes, MD, discusses the benefits of ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.

Naveen Pemmaraju, MD, discusses the potential benefit of rechallenging ruxolitinib in patients with myelofibrosis. 

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

The FDA has accepted an application for ropeginterferon alfa-2b for use as a treatment for patients with polycythemia vera.

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

The first-in-class, synthetic hepcidin mimetic agent PTG-300 is being investigated in an ongoing phase 2 clinical trial, with the goal of introducing a novel therapeutic agent to the limited armamentarium in polycythemia vera.

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Prithviraj Bose, MD, discusses the role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and other novel agents under exploration.

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib. 

The International Working Group for the Prognosis of MDS has identified a distinct subtype of myelodysplastic syndromes based on the presence of SF3B1, a nonheritable genetic mutation that causes the disease.

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

A European panel has recommended approval of luspatercept for the treatment of anemia in patients with myelodysplastic syndromes and beta thalassemia.

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.